March FDA Pipeline

The meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) was approved for protection against meningococcal disease in adolescents and adults aged 11 to 55 years.

FDA approved mometasone (Nasonex, Schering-Plough) for the treatment of nasal polyps in patients aged 18 years and older.